secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001213900-23-038997
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q1 net loss widens to $14.3M; de-prioritizes AML/MDS Phase 3
--------------------------------------------------------------------------------

- Net loss of $14.3M in Q1 2023 vs $2.2M in Q1 2022, driven by increased R&D and warrant liability changes.
- Cash and cash equivalents of $129.4M as of March 31, 2023, boosted by $101.4M net proceeds from January public offering.
- De-prioritized Phase 3 development of briquilimab as conditioning for AML/high-risk MDS; now focusing on chronic spontaneous urticaria and low-intermediate risk MDS.
- Announced positive clinical data from Phase I/II of briquilimab in sickle cell disease: all three patients engrafted, 100% donor myeloid chimerism at 60 days.
- Strengthened board with Vishal Kapoor; appointed Daniel Adelman as Acting CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/0001213900-23-038997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/ea178442-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-038997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer